Medical Cannabis Improves Dystonia Symptoms and Alleviates Pain
In a retrospective pilot study presented at MDS 2021, researchers assessed the effect of medical cannabis treatment on symptoms of dystonia and related pain.
In a retrospective pilot study presented at MDS 2021, researchers assessed the effect of medical cannabis treatment on symptoms of dystonia and related pain.
This case-series described the effect of the COVID-19 pandemic on the incidence of movement disorders in children and adults.
In this retrospective review, study researchers sought to assess the presentation of movement disorders in carriers of C9orf72 hexanucleotide repeat expansions.
To evaluate whether patients with isolated dystonia are at an increased risk for suicidal behavior, researchers administered an anonymous electronic survey.
A phase 3 trial evaluating an investigational therapy for the treatment of pantothenate kinase-associated neurodegeneration did not meet its primary or secondary end points.
The FDA has approved Xeomin (incobotulinumtoxinA; Merz) as a first-line treatment for blepharospasm in adults.
Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.Of the 18 patients with recurrent dystonic symptoms, 7 of the 9 who underwent repeat ventro-oral thalamotomy achieved improvement.
The use of somatosensory temporal discrimination testing did not incite any changes in the mean velocity of index finger movements in either patients with dystonia or healthy controls.
Children with a complex motor disorder, characterized by a combination of movement and posture abnormalities (eg, spasticity and dystonia), were enrolled.
Researchers collected and analyzed data on age at onset, sex, family history of dystonia, and the presence of associated anatomic sites with dystonia.